Timing Of Onset Of Contraceptive Effectiveness In Depo-provera Users. Ii. Effects On Ovarian Function.

dc.creatorPetta, C A
dc.creatorFaúndes, A
dc.creatorDunson, T R
dc.creatorRamos, M
dc.creatorDeLucio, M
dc.creatorFaúndes, D
dc.creatorBahamondes, L
dc.date1998-Nov
dc.date2015-11-27T12:19:24Z
dc.date2015-11-27T12:19:24Z
dc.date.accessioned2018-03-29T00:53:06Z
dc.date.available2018-03-29T00:53:06Z
dc.identifierFertility And Sterility. v. 70, n. 5, p. 817-20, 1998-Nov.
dc.identifier0015-0282
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/9806559
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/194258
dc.identifier9806559
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1294491
dc.descriptionTo determine the timing of onset of contraceptive effectiveness after the first injection of 150 mg of depot medroxyprogesterone acetate (DMPA) administered between days 8 and 13 of the menstrual cycle. Descriptive, prospective study. A tertiary university referral center. Thirty healthy women between 18 and 40 years of age. Volunteers were injected with DMPA between days 8 and 13 (5 women on each day) of the menstrual cycle. Ovarian function determined by serum levels of E2 and progesterone and follicular development evaluated by vaginal ultrasound. In nine (30%) of 30 women studied, DMPA did not prevent ovulation. All ovulations occurred in women receiving DMPA between days 10 and 13 of the cycle. No woman who received injections on day 8 or 9 ovulated. Ovulation suppression was more effective in women with low ovarian activity. All ovulation occurred within 3 days after the injection. A back-up contraceptive method, used after the 7th day of the menstrual cycle, is recommended for up to 7 days after the first injection of DMPA.
dc.description70
dc.description817-20
dc.languageeng
dc.relationFertility And Sterility
dc.relationFertil. Steril.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdolescent
dc.subjectAdult
dc.subjectContraceptive Agents, Female
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectMedroxyprogesterone Acetate
dc.subjectMenstrual Cycle
dc.subjectOvary
dc.subjectProspective Studies
dc.subjectTreatment Outcome
dc.subjectAmericas
dc.subjectBiology
dc.subjectBrazil
dc.subjectClinical Research
dc.subjectContraception
dc.subjectContraceptive Agents
dc.subjectContraceptive Agents, Female
dc.subjectContraceptive Agents, Progestin
dc.subjectContraceptive Effectiveness
dc.subjectContraceptive Methods
dc.subjectDemographic Factors
dc.subjectDepo-provera
dc.subjectDeveloping Countries
dc.subjectFamily Planning
dc.subjectGenitalia
dc.subjectGenitalia, Female
dc.subjectInjectables
dc.subjectLatin America
dc.subjectMedroxyprogesterone Acetate
dc.subjectMenstrual Cycle
dc.subjectMenstruation
dc.subjectOvarian Effects
dc.subjectOvary
dc.subjectOvulation
dc.subjectPhysiology
dc.subjectPopulation
dc.subjectPopulation Dynamics
dc.subjectReproduction
dc.subjectResearch Methodology
dc.subjectResearch Report
dc.subjectSouth America
dc.subjectTime Factors
dc.subjectUrogenital System
dc.titleTiming Of Onset Of Contraceptive Effectiveness In Depo-provera Users. Ii. Effects On Ovarian Function.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución